Advertisement
Screener

AbbVie Inc. (ABBV) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent

2.3 / 5 stars · 55/120 Roast Me

AbbVie Inc. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent

AbbVie Inc. (ABBV) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of -$56.00 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-08.

Discontinued › Income Statement › Unrealized Gains

us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2020-05-08

  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2020-03-31 was -$56.00M.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2019-12-31 was $1.32B.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2019-09-30 was -$33.00M.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2019-06-30 was -$20.00M.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2019 was $1.24B.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2018 was -$197.00M, a 148.52% decline from fiscal 2017.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2017 was $406.00M, a 200.74% increase from fiscal 2016.
  • AbbVie Inc. other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2016 was $135.00M.
Period endOther Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 monthOther Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 monthOther Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 9 monthOther Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month
2020-03-31-$56.00M
10-Q · filed 2020-05-08
$1.26B
derived: sum of 2 quarters · filed 2020-05-08
$1.23B
derived: sum of 3 quarters · filed 2020-05-08
$1.21B
derived: sum of 4 quarters · filed 2020-05-08
2019-12-31$1.32B
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21
$1.29B
derived: sum of 2 quarters · filed 2020-02-21
$1.27B
derived: sum of 3 quarters · filed 2020-02-21
$1.24B
10-K · filed 2020-02-21
2019-09-30-$33.00M
10-Q · filed 2019-11-06
-$53.00M
derived: sum of 2 quarters · filed 2019-11-06
-$78.00M
10-Q · filed 2019-11-06
-$176.00M
derived: sum of 4 quarters · filed 2020-05-08
2019-06-30-$20.00M
10-Q · filed 2019-08-05
-$45.00M
10-Q · filed 2019-08-05
-$143.00M
derived: sum of 3 quarters · filed 2020-05-08
-$171.00M
derived: sum of 4 quarters · filed 2020-05-08
2019-03-31-$25.00M
10-Q · filed 2020-05-08
-$123.00M
derived: sum of 2 quarters · filed 2020-05-08
-$151.00M
derived: sum of 3 quarters · filed 2020-05-08
-$200.00M
derived: sum of 4 quarters · filed 2020-05-08
2018-12-31-$98.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21
-$126.00M
derived: sum of 2 quarters · filed 2020-02-21
-$175.00M
derived: sum of 3 quarters · filed 2020-02-21
-$197.00M
10-K · filed 2020-02-21
2018-09-30-$28.00M
10-Q · filed 2019-11-06
-$77.00M
derived: sum of 2 quarters · filed 2019-11-06
-$99.00M
10-Q · filed 2019-11-06
$328.00M
derived: sum of 4 quarters · filed 2020-02-21
2018-06-30-$49.00M
10-Q · filed 2019-08-05
-$71.00M
10-Q · filed 2019-08-05
$356.00M
derived: sum of 3 quarters · filed 2020-02-21
$348.00M
derived: sum of 4 quarters · filed 2020-02-21
2018-03-31-$22.00M
10-Q · filed 2019-05-03
$405.00M
derived: sum of 2 quarters · filed 2020-02-21
$397.00M
derived: sum of 3 quarters · filed 2020-02-21
$395.00M
derived: sum of 4 quarters · filed 2020-02-21
2017-12-31$427.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21
$419.00M
derived: sum of 2 quarters · filed 2020-02-21
$417.00M
derived: sum of 3 quarters · filed 2020-02-21
$406.00M
10-K · filed 2020-02-21
2017-09-30-$8.00M
10-Q · filed 2018-11-07
-$10.00M
derived: sum of 2 quarters · filed 2018-11-07
-$21.00M
10-Q · filed 2018-11-07
$162.00M
derived: sum of 4 quarters · filed 2019-02-27
2017-06-30-$2.00M
10-Q · filed 2018-08-07
-$13.00M
10-Q · filed 2018-08-07
$170.00M
derived: sum of 3 quarters · filed 2019-02-27
$155.00M
derived: sum of 4 quarters · filed 2019-02-27
2017-03-31-$11.00M
10-Q · filed 2018-05-04
$172.00M
derived: sum of 2 quarters · filed 2019-02-27
$157.00M
derived: sum of 3 quarters · filed 2019-02-27
$139.00M
derived: sum of 4 quarters · filed 2019-02-27
2016-12-31$183.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$168.00M
derived: sum of 2 quarters · filed 2019-02-27
$150.00M
derived: sum of 3 quarters · filed 2019-02-27
$135.00M
10-K · filed 2019-02-27
2016-09-30-$15.00M
10-Q · filed 2017-11-07
-$33.00M
derived: sum of 2 quarters · filed 2017-11-07
-$48.00M
10-Q · filed 2017-11-07
-$187.00M
derived: sum of 4 quarters · filed 2018-02-16
2016-06-30-$18.00M
10-Q · filed 2017-08-07
-$33.00M
10-Q · filed 2017-08-07
-$172.00M
derived: sum of 3 quarters · filed 2018-02-16
-$195.00M
derived: sum of 4 quarters · filed 2018-02-16
2016-03-31-$15.00M
10-Q · filed 2017-05-05
-$154.00M
derived: sum of 2 quarters · filed 2018-02-16
-$177.00M
derived: sum of 3 quarters · filed 2018-02-16
-$190.00M
derived: sum of 4 quarters · filed 2018-02-16
2015-12-31-$139.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16
-$162.00M
derived: sum of 2 quarters · filed 2018-02-16
-$175.00M
derived: sum of 3 quarters · filed 2018-02-16
-$230.00M
10-K · filed 2018-02-16
2015-09-30-$23.00M
10-Q · filed 2016-11-07
-$36.00M
derived: sum of 2 quarters · filed 2016-11-07
-$91.00M
10-Q · filed 2016-11-07
$733.00M
derived: sum of 4 quarters · filed 2017-02-17
2015-06-30-$13.00M
10-Q · filed 2016-08-05
-$68.00M
10-Q · filed 2016-08-05
$756.00M
derived: sum of 3 quarters · filed 2017-02-17
$736.00M
derived: sum of 4 quarters · filed 2017-02-17
2015-03-31-$55.00M
10-Q · filed 2016-05-06
$769.00M
derived: sum of 2 quarters · filed 2017-02-17
$749.00M
derived: sum of 3 quarters · filed 2017-02-17
$738.00M
derived: sum of 4 quarters · filed 2017-02-17
2014-12-31$824.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17
$804.00M
derived: sum of 2 quarters · filed 2017-02-17
$793.00M
derived: sum of 3 quarters · filed 2017-02-17
$781.00M
10-K · filed 2017-02-17
2014-09-30-$20.00M
10-Q · filed 2015-11-06
-$31.00M
derived: sum of 2 quarters · filed 2015-11-06
-$43.00M
10-Q · filed 2015-11-06
-$564.00M
derived: sum of 4 quarters · filed 2016-02-19
2014-06-30-$11.00M
10-Q · filed 2015-08-07
-$23.00M
10-Q · filed 2015-08-07
-$544.00M
derived: sum of 3 quarters · filed 2016-02-19
-$586.00M
derived: sum of 4 quarters · filed 2016-02-19
2014-03-31-$12.00M
10-Q · filed 2015-05-08
-$533.00M
derived: sum of 2 quarters · filed 2016-02-19
-$575.00M
derived: sum of 3 quarters · filed 2016-02-19
-$591.00M
derived: sum of 4 quarters · filed 2016-02-19
2013-12-31-$521.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19
-$563.00M
derived: sum of 2 quarters · filed 2016-02-19
-$579.00M
derived: sum of 3 quarters · filed 2016-02-19
-$598.00M
10-K · filed 2016-02-19
2013-09-30-$42.00M
10-Q · filed 2014-11-07
-$58.00M
derived: sum of 2 quarters · filed 2014-11-07
-$77.00M
10-Q · filed 2014-11-07
$75.00M
derived: sum of 4 quarters · filed 2015-02-20
2013-06-30-$16.00M
10-Q · filed 2014-08-07
-$35.00M
10-Q · filed 2014-08-07
$117.00M
derived: sum of 3 quarters · filed 2015-02-20
$116.00M
derived: sum of 4 quarters · filed 2015-02-20
2013-03-31-$19.00M
10-Q · filed 2014-05-09
$133.00M
derived: sum of 2 quarters · filed 2015-02-20
$132.00M
derived: sum of 3 quarters · filed 2015-02-20
$131.00M
derived: sum of 4 quarters · filed 2015-02-20
2012-12-31$152.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20
$151.00M
derived: sum of 2 quarters · filed 2015-02-20
$150.00M
derived: sum of 3 quarters · filed 2015-02-20
$150.00M
10-K · filed 2015-02-20
2012-09-30-$1.00M
10-Q · filed 2013-11-12
-$2.00M
derived: sum of 2 quarters · filed 2013-11-12
-$2.00M
10-Q · filed 2013-11-12
2012-06-30-$1.00M
10-Q · filed 2013-08-09
-$1.00M
10-Q · filed 2013-08-09
2011-12-31$7.00M
10-K · filed 2014-02-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
Merck & Co., Inc. (MRK)United States$365.215B99.96
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60